Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017

Transcription

1 Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice President and Global Chief Medical Officer Nicholas Spadea-Anello Structural Heart-LAAC Vice President and General Manager 1

2 Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of Forward-looking statements may be identified by words like anticipate, expect, project, believe, plan, estimate, intend and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings Risk Factors and Safe Harbor for Forward-Looking Statements. Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forwardlooking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates. 2 2 Regulatory Disclaimers: LOTUS Edge TM and ACURATE neo TM Valves may only be used in countries where they are approved for use. LOTUS Edge Valve and isleeve TM are not available for sale in the European Economic Area. For education purposes only. LOTUS Edge TM Valve and isleeve TM are investigational devices in the United States and are not available for sale. WATCHMAN FLX TM is pending CE Mark. Not available for use or sale in the United States.

3 Broadest Portfolio to Drive IC Category Leadership Coronary Therapies Structural Heart Stents Complex PCI PCI Guidance TAVR LAAC Mitral Coronary Therapies Structural Heart Total Cardiology 2016 Market Size $7.5B $3B $10.5B 5yr CAGR ( ) 1% +17% +7% Est Market Size $8.0B $6.5B $14.5B Est Share Position #1 #2 #1 3 3

4 Diversifying into Faster Growth IC Markets Maintain coronary therapies leadership + grow structural heart platforms = healthy IC portfolio diversification 2016 BSX IC Revenue Mix 2021E 10% 36% 54% ~40% ~30% Market Size = $10.5B Structural Heart Complex PCI Stents ~30% Market Size = $14.5B 4 4

5 Compelling TAVR Portfolio Expand Your Reach More Options for Better Outcomes ACURATE neo Aortic Valve System EU Commercial expansion with ACURATE neo TF and TA Launch next generation ACURATE neo AS H2:18E LOTUS Edge Aortic Valve System EU launch Q1:18E and U.S. launch mid-2018e Accessory Devices Market leading Safari2 Guidewire isleeve Expandable Sheath Clinical Programs LOTUS Edge REPRISE IV Intermediate Risk U.S. study Enrollment mid-2018e ACURATE neo U.S. IDE* Enrollment H2:18E 5 E = expected *Pending

6 WATCHMAN LAAC Device Global Leadership WATCHMAN Commercial Activities Therapy development efforts continue Focus on penetrating U.S. indicated population 1% of penetration = $250M TV campaign showing strong patient activation Pilot market growth is above national average Main CMS DRG for LAAC increased ~11% on Oct 1 Received CE Mark for an updated WATCHMAN DFU Allows for DAPT + shorter OAT duration post implant Clinical Milestones Completed Japan Salute IDE clinical trial in Q3 PREVAIL 5-year outcomes highlighted as LBCT Thursday Product Pipeline 6 WATCHMAN FLX E = expected WATCHMAN FLX PINNACLE FLX U.S. IDE enrollment mid-2018e FLXibility EU Post-Market Study enrollment mid 2018E

7 Unrivaled DES Innovation YTD 2017: DES growth at market rates despite double digit 2016 growth comparison Comprehensive clinical science: SYNERGY studied in ~20,000 patients Unique and differentiated tiered portfolio Future product innovation: 48 mm SYNERGY 4.5 / 5.0mm SYNERGY Short DAPT indication Trans-radial enhanced NG DES system #1 US DES Market Share Strong DES Portfolio and U.S. Market Leader for 14 quarters 7 7

8 Unmatched Complex PCI and Imaging Portfolios Clear Leadership in $2.5B Complex PCI Market Continued Investment in Imaging Portfolio New Devices for cpci Robust and consistent product cadence continues in

9 IC Category Leadership via Breadth of Portfolio 9